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Postrenal transplantation diabetes mellitus (PTDM), or new-onset diabetes after organ transplantation, is an important chronic 
transplant-associated complication. Similar to type 2 diabetes, decreased insulin secretion and increased insulin resistance are 
important to the pathophysiologic mechanism behind the development of PTDM. However, β-cell dysfunction rather than insu-
lin resistance seems to be a greater contributing factor in the development of PTDM. Increased age, family history of diabetes, 
ethnicity, genetic variation, obesity, and hepatitis C are partially accountable for an increased underlying risk of PTDM in renal 
allograft recipients. In addition, the use of and kinds of immunosuppressive agents are key transplant-associated risk factors. Re-
cently, a number of genetic variants or polymorphisms susceptible to immunosuppressants have been reported to be associated 
with calcineurin inhibition-induced β-cell dysfunction. The identification of high risk factors of PTDM would help prevent PTDM 
and improve long-term patient outcomes by allowing for personalized immunosuppressant regimens and by managing cardio-
vascular risk factors. 
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INTRODUCTION
During the immediate period after solid organ transplantation, 
rejection of the transplanted organ as well as the short-term 
survival rate of the patient is of primary concern. Overcoming 
the shortcomings of currently available surgical techniques 
and immunosuppressants would allow for a longer life expec-
tancy in more patients. Accordingly, greater emphasis has been 
placed on caring for chronic transplant-associated morbidi-
ties, which are the primary determinant of expectancy and 
quality of life in the long-term post-transplantation periods. 
The increased prevalence of macrovascular events in transplant 
recipients compared to non-transplant subjects remains a piv-
otal challenge to overcome. Among the established risk factors 
for the development of cardiovascular events in transplant re-
cipients, attention and research has focused on abnormal glu-
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cose homeostasis in kidney transplant recipients. Therefore 
this review focuses on what is currently known about how ge-
netics and pancreatic β-cell dysfunction related to the devel-
opment of diabetes in kidney recipients. 
INCIDENCE OF POSTRENAL 
TRANSPLANTATION DIABETES MELLITUS 
Hyperglycemia after renal transplantation leads to the devel-
opment of microvascular morbidity as well as accelerated mac-
rovascular events, resulting in reduced recipient survival [1]. 
In this regard, aggravation of pre-existing diabetes as well as 
new-onset transplant-associated hyperglycemia encompass-
ing new onset diabetes mellitus (DM), impaired fasting glu-
cose (IFG), and impaired glucose tolerance (IGT) have been 
introduced as gluco-metabolic targets in an effort to reduce 
the risk of developing chronic transplant-associated morbidity 
and mortality by implementing proper management approach-
es during pre- and post-transplant stages [2]. Postrenal trans-
plantation diabetes mellitus (PTDM), first described by Starzl 
et al. [3] in 1964, is defined as new-onset diabetes after solid 
organ transplantation. The definition of diabetes according to 
the American Diabetes Association (ADA) is a fasting plasma 
glucose [FPG] ≥7.0 mmol/L or a 2-hour post-load glucose 
≥11.1 mmol/L, and this is routinely adopted when diagnosing 
PTDM. However, the incidence and prevalence of PTDM var-
ies among studies depending on the criteria used to diagnose 
diabetes, the usage or kinds of immunosuppressants, charac-
teristics of the subject population, and time after transplanta-
tion [4]. In the 1970s and early 1980s, steroids were considered 
the gold standard drug-of-choice and 40% to 60% of transplant 
recipients developed DM [5,6]. Even with the advent of cyclo-
sporine A (CsA) in 1978, the prevalence of PTDM ranges 
widely from 5% to 45% [7-12], which is 2 to 9 times more than 
that of DM in an age- and sex-matched general population. A 
meta-analysis involving 19 observational studies and controlled 
trials reported that the rates of PTDM in the first post-trans-
plantation year range from 2% to 50%. Two of the largest epi-
demiologic studies investigating the incidence of PTDM in 
subjects on the waiting list for renal transplantation and trans-
plant recipients [13,14] demonstrated a 6% annual baseline 
incidence of new onset diabetes for the wait-listed subjects, 
and a 14% to 16% increase in the incidence of PTDM during 
the first post-transplantation year for transplant recipients. In 
the Korean population, it was previously reported that the 
overall incidence of PTDM was 39% at 1 year after transplan-
tation and 35.1% at 7 years after transplantation [15]. Based on 
these results, PTDM might be especially accelerated in the first 
few post-transplantation months by the superimposition of 
transplant-related factors on baseline risks. 
TRANSPLANT-ASSOCIATED RISK FACTORS 
AND TRADITIONAL TYPE 2 DIABETES RISK 
FACTORS OF PTDM
The risk factors associated with PTDM have been examined in 
many studies. Underlying baseline risk factors such as in-
creased age, family history of diabetes, ethnicity, genetic varia-
tion, obesity, and hepatitis C are partially accountable for an 
increased underlying risk of PTDM in renal allograft recipients 
[16-18]. Non-modifiable risk factors of PTDM appear to be 
greater for patients who are older at the time of transplanta-
tion and have a familial history of diabetes [19]. Kidney trans-
plant recipients older than 40 years of age are at greater risk of 
PTDM than younger recipients [11]. Gaining weight after 
transplantation, particularly among kidney transplant recipi-
ents, and infection with the hepatitis C virus [20] are modifi-
able risk factors for the development of PTDM. Similar to type 
2 diabetes (T2D), weight gain after transplantation leads to in-
sulin resistance [21] resulting in the development of PTDM. 
 In terms of transplant-related risk factors, usage and types 
of immunosuppressive agents are key to the aggravation or 
development of DM. PTDM is a major adverse effect of im-
munosuppressants. The diabetogenic effect of glucocorticoids, 
which has been well known since the early transplantation era, 
mainly results from both decreased peripheral glucose utiliza-
tion and increased hepatic glucose production. The introduc-
tion of the 2nd generation of immunosuppressants of calci-
neurin inhibitors such as CsA and tacrolimus (Tac) into the 
field of transplantation has improved the outcome of organ 
transplants. However, their widespread therapeutic use is hin-
dered by numerous reciprocal side effects shared between both 
drugs. Among them, new onset DM after transplantation, also 
known as PTDM, is of particular concern because of its fre-
quent occurrence [22] and its associations with increased risk 
of cardiovascular diseases and lower survival rates.
 Although the clinical features of T2D, such as insidious de-
velopment, asymptomatic periods, etc., are similar to those of 
PTDM, some questions still remain regarding the incidence of 
PTDM among different ethnic groups. Interestingly, non-Cau-
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casian kidney transplant recipients such as African-Ameri-
cans, Hispanics, and Koreans are at greater risk of developing 
PTDM. These differences might be partially related to the 
pathophysiological development or aggravation of diabetes. 
The pathophysiologic nature of T2D is characterized by a pro-
gressive decline in pancreatic β-cell function and worsening 
insulin resistance, resulting in the failure of islets to respond to 
oral anti-diabetic drugs. However, the major determinant fac-
tors of PTDM remain controversial and there is some debate 
regarding whether the pathophysiology of PTDM is the result 
of decreased insulin secretion, increased insulin resistance, or 
both. For example, Ekstrand et al. [23] stated that insulin re-
sistance and decreased insulin secretion may both be respon-
sible, while Midtvedt et al. [24] suggested that insulin resis-
tance may be the major contributor, and Shimizu et al. [25] re-
ported that insulin resistance was improved after transplanta-
tion. Finally, in a well-designed 6-year prospective study, Ha-
gen et al. [26] reported that impaired insulin secretion was the 
dominant mechanism for the development of PTDM. We have 
demonstrated that β-cell dysfunction was a major contribut-
ing factor to the development of PTDM in Korean subjects 
[15], which is consistent with Hagen et al.’s results. As we pre-
viously described, hyperglycemia after transplantation might 
be accelerated by the superimposition of transplant-related 
factors on baseline risks. Considering the characteristics of 
Korean patients with T2D, whose secretory β-cell dysfunction 
was a major contributing factor to the development and ag-
gravation of hyperglycemia [27,28], different pharmacokinetic 
responses may augment the diabetogenic impact of immuno-
suppressants and superimpose upon conventional susceptible 
risks in the Korean population. In this regard, we also reported 
that the interaction between traditional genetic risk factors and 
transplant-associated risk factors such as calcineurin inhibi-
tors plays an important role in the augmentation of established 
and new onset diabetes [29].
 The association between PTDM and calcineurin inhibitor 
drugs is well-established. Previous in vitro studies on purified 
islets and insulin-producing β-cells have proposed several dia-
betogenic actions for CsA and Tac. Both drugs impair insulin 
secretion [30-33], decrease insulin content of the β-cell [34,35] 
and impair insulin transcription [36,37], although the primary 
mechanisms are not yet fully understood. In insulin-secreting 
cells, calcineurin is involved in the stimulation of insulin gene 
transcription through the activation of the transcription factor 
nuclear factor of activated T-cells (NFAT) [38]. Indeed, mice 
deficient in calcineurin B1 were shown to develop DM due to 
insufficient insulin production, while transgenic expression of 
constitutively active NFAT protected against DM [39]. In an-
other study on immunosuppressants, rapamycin inhibited the 
mammalian target of rapamycin without affecting calcineurin 
activity, and also inhibited glucose-stimulated insulin secretion 
(GSIS) in β-cells [40,41]. Although the therapeutic ranges of 
Tac and rapamycin are comparable, the potency of rapamycin 
in inhibiting insulin secretion seemed to be much lower than 
that of Tac in our study [29]. This may partly explain why ra-
pamycin has less diabetogenic activity. However, the role of ra-
pamycin in PTDM is still under investigation [17,42]. Recent-
ly, the suppression of carbohydrate metabolism by rapamycin 
was suggested as a possible mechanism for the inhibition of 
insulin secretion [43]. However, the mechanism of action of 
rapamycin in the insulin secretory pathway is largely unknown.
PATHOPHYSIOLOGY OF PTDM: β-CELL 
DYSFUNCTION RATHER THAN INSULIN 
RESISTANCE 
Diabetes is caused by an imbalance in insulin production and 
peripheral insulin sensitivity. Despite some controversy, insu-
lin secretory dysfunction is thought to be the dominant mech-
anism for the development of PTDM. We found that β-cell 
dysfunction plays a major role in the development of PTDM, 
which is consistent with previous reports [15,21]. On the issue 
of ‘Diabetes Care’ [15], we enrolled a total of 77 subjects with 
normal glucose tolerance (NGT), and an oral glucose toler-
ance test (OGTT) was performed 1 week before transplanta-
tion and repeated at 1 and 7 years after transplantation [15]. 
The overall incidence of PTDM was 39% at 1 year and 35.1% at 
7 years post-transplantation. 
 The following conclusions were drawn based on the results 
of these studies: first, the fasting and 2-hour plasma glucose 
levels before transplantation in the IGT and PTDM after trans-
plantation groups were significantly higher than those in the 
NGT after transplantation group. Second, patients with de-
creased insulin-secretory capacity, rather than decreased insu-
lin sensitivity, were predisposed to developing PTDM. Com-
pared with values before transplantation, the indices of insulin 
secretion and insulin sensitivity deteriorated at 1 year after 
transplantation. The insulin sensitivity index (ISI), represent-
ing insulin sensitivity, was not statistically different among 
groups after transplantation. However, the area under the curve 
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of insulin on OGTT, representing insulin secretory function, 
was significantly lower in the PTDM group than in the NGT 
group. Proinsulin and proinsulin/insulin ratios have been pro-
posed as indices for reduced maximum β-cell secretory capac-
ity in patients with type 1 and type 2 diabetes [44,45]. Maxi-
mum β-cell secretory capacity plays a pivotal role in the re-
sponse to glucose loading, which is associated with deteriora-
tion in glucose tolerance. In our study, proinsulin/insulin ra-
tios in the IGT and PTDM groups were significantly higher 
than in the NGT group at both pre- and post-transplantation 
periods. Taken together, this indicates that β-cell dysfunction 
was a more important factor for the development of PTDM.
GENETIC RISK FACTORS OF PTDM AND 
CLINICAL IMPLICATIONS OF ZINC 
TRANSPORTER-8 GENE IN RENAL 
TRANSPLANTATION 
PTDM may reflect a genetic predisposition to diabetes influ-
enced by multiple environmental factors. Twenty-six percent 
of patients with a family history of diabetes develop PTDM, 
while only 14% of patients without a family history of diabetes 
develop PTDM [46]. This finding suggests that genetic variants 
typically associated with T2D are also likely associated with 
PTDM. However, only a few of the genetic polymorphisms as-
sociated with T2D have been studied in detail in transplant 
patients. Some studies have shown a significant association 
between PTDM and genetic polymorphisms. These polymor-
phisms were associated with genes involving insulin secretion 
(KCNJ11, HNF4A, NFATc4, ENPP1/PC-1 [K121Q], CCL5, 
VDR) [47-52], insulin resistance (adiponectin, adiponectin re-
ceptor 1, PAI-1) [53-55], and oxidative stress (glutathione S-
transferase gene, SOD) [56,57]. One functional study and our 
three genetic association studies comprising a renal allograft 
cohort found that TCF7L2, a T2D susceptibility gene, led to a 
two-fold increase in the risk of T2D. In addition, we found 
that the TCF7L2 rs7903146 genetic variation is also signifi-
cantly associated with an increased risk of developing PTDM 
in kidney transplant recipients [58]. Zinc found in the zinc 
transporter-8 (ZnT-8) gene is involved in modulating insulin 
secretion. The R325W (rs13266634) non-synonymous poly-
morphism in the islet-specific zinc transporter protein gene 
SLC30A8 is associated with T2D and also may be associated 
with a defect in insulin secretion. To investigate the association 
between genetic variations in the SLC30A8 gene and PTDM 
in renal-transplant recipients [59], we recruited a total of 624 
renal-allograft recipients without a documented history of di-
abetes. The prevalence of PTDM was 33.8% in patients with 
the R/R genotype, 26.8% in those with the R/W genotype, and 
19.8% in those with the W/W genotype. In addition, a strong 
association between the number of W alleles and PTDM risk 
reduction (P=0.007) was found. Patients with at least one W 
allele had a lower risk of PTDM compared to those with the R/
R genotype (R/W RR, 0.78, P=0.126; W/W RR, 0.52, P=0.007). 
The effect of the SLC30A8 genotype remained significant even 
after adjusting for age, gender, body weight gain, and type of 
immunosuppressant (R/W hazard ratio [HR], 0.77, P=0.114; 
W/W HR, 0.58, P=0.026). Therefore the SLC30A8 rs13266634 
gene variation appears to be associated with protection against 
the development of PTDM in renal-allograft recipients. 
 There is an association between PTDM and 17 single nucle-
otide polymorphisms (SNPs) located within 15 genes. Genome-
wide association studies determined that these genes were re-
lated to diabetes susceptibility [60]. We found an association 
between the development of PTDM and the following SNPs: 
HHEX (rs1111875, rs7923837, and rs5015480), CDKAL1 
rs10946398, CDKN2A/B rs10811661, IGF2BP2 rs4402960, 
FTO rs8050136, WFS1 rs734312, JAZF1 rs864745, CDC123/
CAMK1D  rs12779790, TSPAN8  rs7961581, THADA 
rs7578597, ADAMTS9 rs4607103, NOTCH2 rs1092391, and 
KCNQ1 rs2237892. Six loci were significantly associated with 
PTDM development: HHEX rs1111875 (odds ratio [OR], 1.47; 
P=0.007), HHEX rs7923837 (OR, 2.32; P=0.014), HHEX 
rs5015480 (OR, 1.59; P=0.003), CDKAL1 rs10946398 (OR, 
1.43; P=0.008), CDKN2A/B rs10811661 (OR, 1.33; P=0.039), 
and KCNQ1 rs2237892 (OR, 1.46; P=0.009).
 Recently, we investigated the functional aspect of the zinc 
transporter gene, based on the hypothesis that the polymor-
phic residue at position 325 of ZnT-8 might determine suscep-
tibility to CsA suppression of insulin secretion [29]. INS-1E 
cells expressing the W325 variant showed enhanced GSIS and 
were less sensitive to CsA suppression of GSIS. A reduced 
number of insulin granule fusion events accompanied the de-
crease in insulin secretion in CsA-treated cells expressing ZnT-
8 R325; however, ZnT-8 W325-expressing cells exhibited re-
sistance to the dampening of insulin granule fusion by CsA 
and transported zinc ions into secretory vesicles more efficient-
ly. Both Tac and rapamycin caused similar suppression of GSIS 
in cells expressing ZnT-8 R325. However, cells expressing ZnT-8 
W325 were resistant to Tac, but not to rapamycin. Overexpres-
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sion of the Down’s syndrome candidate region-1 (DSCR1), an 
endogenous calcineurin inhibitor, and subsequent calcineurin 
inhibition significantly reduced GSIS in cells expressing the 
R325 but not the W325 variant, suggesting that differing sus-
ceptibility to CsA may be due to different interactions with 
calcineurin. These data suggest that the ZnT-8 W325 variant is 
protective against CsA-induced suppression of insulin secre-
tion. Tolerance of ZnT-8 W325 to calcineurin activity may ac-
count for its protective effect in PTDM.
CONCLUSIONS
DM is a serious and frequent complication of renal transplan-
tation. Although DM ultimately results from decreased insulin 
secretion and increased insulin resistance, our data suggest 
that β-cell dysfunction, rather than insulin resistance, may be 
the main contributing factor in the development of PTDM. 
PTDM is not always permanent and may resolve within weeks 
or months, sometimes without treatment. The aforementioned 
risk factors seem to be related to the different courses of PTDM. 
The ability to predict a patient’s risk for developing PTDM 
would be of considerable benefit in selecting appropriate im-
munosuppressive regimens for individuals.
 Genotyping diabetes-related polymorphisms is one possible 
method for predicting a patient’s risk for developing PTDM. 
Our data suggest that genetic variations such as TCF7L2, SL-
C30A8, HHEX, CDKAL1, CDKN2A/B, and KCNQ1 are asso-
ciated with PTDM in Korea. Notably, SLC30A8 encodes for 
β-cell-specific ZnT-8. The same allelic variant (which is a sub-
stitution of tryptophan for arginine at residue 325) of ZnT-8 is 
also associated with reduced incidence of PTDM in renal al-
lograft recipients (Fig. 1). A single nucleotide substitution in 
SLC30A8 confers resistance to CsA-induced β-cell dysfunc-
tion by altering susceptibility to calcineurin inhibition. Our 
data suggest that ZnT-8 might be an important molecule con-
necting calcineurin inhibition by CsA to downregulation of 
β-cell insulin secretion, and this signaling pathway might be a 
new therapeutic target for the treatment of CsA-induced β-cell 
complications that occur after organ transplantation.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
REFERENCES
1. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, 
Markell MS, Distant DA, Hong JH, Sommer BG, Friedman 
EA. Diabetes mellitus after renal transplantation: as deleteri-
ous as non-transplant-associated diabetes? Transplantation 
1998;65:380-4.
2. Bloom RD, Crutchlow MF. New-onset diabetes mellitus in the 
kidney recipient: diagnosis and management strategies. Clin J 
Am Soc Nephrol 2008;3 Suppl 2:S38-48.
3. Starzl TE, Marchioro TL, Rifkind D, Holmes JH, Rowlands DT 
Jr, Waddell WR. Factors in successful renal transplantation. 
Surgery 1964;56:296-318.
4. Crutchlow MF, Bloom RD. Transplant-associated hyperglyce-
mia: a new look at an old problem. Clin J Am Soc Nephrol 2007; 
2:343-55.
5. Hill CM, Douglas JF, Rajkumar KV, McEvoy J, McGeown MG. 
Fig. 1. Schematic representation of vesicular zinc transporter-8 
(ZnT-8) expression and R325W polymorphism in pancreatic 
islet β-cells. The single-nucleotide polymorphism rs13266634 
of SLC30A8 is associated with postrenal transplantation diabe-
tes mellitus (PTDM) in renal allograft recipients, as demon-
strated by Kang et al. [59]. SLC30A8 encodes ZnT-8, which is 
specifically expressed in β-cells. ZnT-8 promotes zinc accumu-
lation in secretory vesicles, and vesicular zinc is important for 
the formation of the zinc-insulin hexamer. Calcineurin is the 
intracellular target of the immunosuppressive drugs CsA and 
tacrolimus, and calcineurin activity is known to play a role in 
insulin gene transcription through the regulation of NFATc 
activity (Reproduced from Kim I, et al. Pharmacogenomics J 
2011;11:191-8, with permission from Nature Publishing Group, 
a division of Macmillan Publishers Limited) [29].
204
Lee HC
Diabetes Metab J 2012;36:199-206 http://e-dmj.org
Glycosuria and hyperglycaemia after kidney transplantation. 
Lancet 1974;2:490-2.
6. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some charac-
teristics of steroid diabetes: a study in renal-transplant recipi-
ents receiving high-dose corticosteroid therapy. Diabetes Care 
1983;6:23-5.
7. Rao M, Jacob CK, Shastry JC. Post-renal transplant diabetes 
mellitus: a retrospective study. Nephrol Dial Transplant 1992;7: 
1039-42.
8. Ahn KJ, Kim YS, Lee HC, Park K, Huh KB. Clinical character-
istics and possible risk factors in postrenal transplant diabetes 
mellitus. Transplant Proc 1992;24:1581-2.
9. Basri N, Aman H, Adiku W, Baraqdar A, Bonatero I, Neza-
muddin N. Diabetes mellitus after renal transplantation. Trans-
plant Proc 1992;24:1780-1.
10. Sumrani NB, Delaney V, Ding ZK, Davis R, Daskalakis P, Fried-
man EA, Butt KM, Hong JH. Diabetes mellitus after renal trans-
plantation in the cyclosporine era: an analysis of risk factors. 
Transplantation 1991;51:343-7.
11. von Kiparski A, Frei D, Uhlschmid G, Largiader F, Binswanger 
U. Post-transplant diabetes mellitus in renal allograft recipients: 
a matched-pair control study. Nephrol Dial Transplant 1990;5: 
220-5.
12. Lee HC, Nam MS, Nam SY, Cha BS, Lee JH, Song YD, Lee EJ, 
Lim SK, Kim KR, Kim YS, Park K, Huh KB. Posttransplant di-
abetes mellitus after renal transplantation in Korea. Transplant 
Proc 1996;28:1159-60.
13. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Roca-
fort L, Haider S, Woodworth TG, Brennan DC. Incidence and 
cost of new onset diabetes mellitus among U.S. wait-listed and 
transplanted renal allograft recipients. Am J Transplant 2003;3: 
590-8.
14. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes melli-
tus after kidney transplantation in the United States. Am J 
Transplant 2003;3:178-85.
15. Hur KY, Kim MS, Kim YS, Kang ES, Nam JH, Kim SH, Nam 
CM, Ahn CW, Cha BS, Kim SI, Lee HC. Risk factors associated 
with the onset and progression of posttransplantation diabetes 
in renal allograft recipients. Diabetes Care 2007;30:609-15.
16. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrom J, Leivestad 
T, Egeland T, Fauchald P. Glucose intolerance after renal trans-
plantation depends upon prednisolone dose and recipient age. 
Transplantation 1997;64:979-83.
17. Rodrigo E, Fernandez-Fresnedo G, Valero R, Ruiz JC, Pinera 
C, Palomar R, Gonzalez-Cotorruelo J, Gomez-Alamillo C, Arias 
M. New-onset diabetes after kidney transplantation: risk fac-
tors. J Am Soc Nephrol 2006;17(12 Suppl 3):S291-5.
18. Markell M. New-onset diabetes mellitus in transplant patients: 
pathogenesis, complications, and management. Am J Kidney 
Dis 2004;43:953-65.
19. Lanerolle RD, de Abrew K, Fernando DJ, Sheriff MH. Post-re-
nal transplant diabetes in Sri Lanka. Transplant Proc 1996;28: 
1945-7.
20. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange 
KC. Association of hepatitis C with posttransplant diabetes in 
renal transplant patients on tacrolimus. J Am Soc Nephrol 2002; 
13:1374-80.
21. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, 
Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB. beta-Cell 
dysfunction rather than insulin resistance is the main contrib-
uting factor for the development of postrenal transplantation 
diabetes mellitus. Transplantation 2001;71:1417-23.
22. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes 
mellitus in patients receiving calcineurin inhibitors: a system-
atic review and meta-analysis. Am J Transplant 2004;4:583-95.
23. Ekstrand AV, Eriksson JG, Gronhagen-Riska C, Ahonen PJ, 
Groop LC. Insulin resistance and insulin deficiency in the 
pathogenesis of posttransplantation diabetes in man. Trans-
plantation 1992;53:563-9.
24. Midtvedt K, Hartmann A, Hjelmesaeth J, Lund K, Bjerkely BL. 
Insulin resistance is a common denominator of post-transplant 
diabetes mellitus and impaired glucose tolerance in renal 
transplant recipients. Nephrol Dial Transplant 1998;13:427-31.
25. Shimizu M, Iino Y, Terashi A. Improvement of insulin sensi-
tivity after renal transplantation measured by a glucose clamp 
technique. Nihon Ika Daigaku Zasshi 1998;65:50-4.
26. Hagen M, Hjelmesaeth J, Jenssen T, Morkrid L, Hartmann A. 
A 6-year prospective study on new onset diabetes mellitus, in-
sulin release and insulin sensitivity in renal transplant recipi-
ents. Nephrol Dial Transplant 2003;18:2154-9.
27. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunc-
tion and insulin resistance in the pathogenesis of Korean type 
2 diabetes mellitus. Metabolism 2001;50:590-3.
28. Rhee SY, Woo JT. The prediabetic period: review of clinical as-
pects. Diabetes Metab J 2011;35:107-16.
29. Kim I, Kang ES, Yim YS, Ko SJ, Jeong SH, Rim JH, Kim YS, 
Ahn CW, Cha BS, Lee HC, Kim CH. A low-risk ZnT-8 allele 
(W325) for post-transplantation diabetes mellitus is protective 
against cyclosporin A-induced impairment of insulin secre-
tion. Pharmacogenomics J 2011;11:191-8.
205
Risk factors of post-renal transplant diabetes mellitus 
Diabetes Metab J 2012;36:199-206http://e-dmj.org
30. Nielsen JH, Mandrup-Poulsen T, Nerup J. Direct effects of cy-
closporin A on human pancreatic beta-cells. Diabetes 1986;35: 
1049-52.
31. Robertson RP. Cyclosporin-induced inhibition of insulin se-
cretion in isolated rat islets and HIT cells. Diabetes 1986;35: 
1016-9.
32. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory ef-
fects of immunosuppressive drugs on insulin secretion from 
HIT-T15 cells and Wistar rat islets. Transplantation 2002;73: 
353-7.
33. Polastri L, Galbiati F, Bertuzzi F, Fiorina P, Nano R, Gregori S, 
Aldrighetti L, Pozza G, Secchi A, Adorini L, Davalli AM. Se-
cretory defects induced by immunosuppressive agents on hu-
man pancreatic beta-cells. Acta Diabetol 2002;39:229-33.
34. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson 
RP. Effects of tacrolimus (FK506) on human insulin gene ex-
pression, insulin mRNA levels, and insulin secretion in HIT-
T15 cells. J Clin Invest 1996;98:2786-93.
35. Uchizono Y, Iwase M, Nakamura U, Sasaki N, Goto D, Iida M. 
Tacrolimus impairment of insulin secretion in isolated rat is-
lets occurs at multiple distal sites in stimulus-secretion coupling. 
Endocrinology 2004;145:2264-72.
36. Lawrence MC, Bhatt HS, Watterson JM, Easom RA. Regula-
tion of insulin gene transcription by a Ca(2+)-responsive path-
way involving calcineurin and nuclear factor of activated T cells. 
Mol Endocrinol 2001;15:1758-67.
37. Oetjen E, Baun D, Beimesche S, Krause D, Cierny I, Blume R, 
Dickel C, Wehner S, Knepel W. Inhibition of human insulin 
gene transcription by the immunosuppressive drugs cyclospo-
rin A and tacrolimus in primary, mature islets of transgenic 
mice. Mol Pharmacol 2003;63:1289-95.
38. Lawrence MC, Bhatt HS, Easom RA. NFAT regulates insulin 
gene promoter activity in response to synergistic pathways in-
duced by glucose and glucagon-like peptide-1. Diabetes 2002; 
51:691-8.
39. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crab-
tree GR, Kim SK. Calcineurin/NFAT signalling regulates pan-
creatic beta-cell growth and function. Nature 2006;443:345-9.
40. Zhang N, Su D, Qu S, Tse T, Bottino R, Balamurugan AN, Xu J, 
Bromberg JS, Dong HH. Sirolimus is associated with reduced 
islet engraftment and impaired beta-cell function. Diabetes 
2006;55:2429-36.
41. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, 
Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibow-
itz G. mTOR inhibition by rapamycin prevents beta-cell adap-
tation to hyperglycemia and exacerbates the metabolic state in 
type 2 diabetes. Diabetes 2008;57:945-57.
42. Veroux M, Corona D, Giuffrida G, Gagliano M, Sorbello M, 
Virgilio C, Tallarita T, Zerbo D, Giaquinta A, Fiamingo P, 
Macarone M, Li Volti G, Caglia P, Veroux P. New-onset diabe-
tes mellitus after kidney transplantation: the role of immuno-
suppression. Transplant Proc 2008;40:1885-7.
43. Shimodahira M, Fujimoto S, Mukai E, Nakamura Y, Nishi Y, 
Sasaki M, Sato Y, Sato H, Hosokawa M, Nagashima K, Seino Y, 
Inagaki N. Rapamycin impairs metabolism-secretion coupling 
in rat pancreatic islets by suppressing carbohydrate metabolism. 
J Endocrinol 2010;204:37-46.
44. Heaton DA, Millward BA, Gray IP, Tun Y, Hales CN, Pyke DA, 
Leslie RD. Increased proinsulin levels as an early indicator of 
B-cell dysfunction in non-diabetic twins of type 1 (insulin-de-
pendent) diabetic patients. Diabetologia 1988;31:182-4.
45. Roder ME, Porte D Jr, Schwartz RS, Kahn SE. Disproportion-
ately elevated proinsulin levels reflect the degree of impaired B 
cell secretory capacity in patients with noninsulin-dependent 
diabetes mellitus. J Clin Endocrinol Metab 1998;83:604-8.
46. Sumrani N, Delaney V, Ding Z, Davis R, Daskalakis P, Fried-
man EA, Butt KM, Hong JH. Posttransplant diabetes mellitus 
in cyclosporine-treated renal transplant recipients. Transplant 
Proc 1991;23(1 Pt 2):1249-50.
47. Tavira B, Coto E, Torres A, Diaz-Corte C, Diaz-Molina B, Orte-
ga F, Arias M, Diaz JM, Selgas R, Lopez-Larrea C, Ruiz-Ortega 
M, Ortiz A, Gonzalez E, Campistol JM, Alvarez V; The Phar-
macogenetics of tacrolimus REDINREN study group. Associa-
tion between a common KCNJ11 polymorphism (rs5219) and 
new-onset posttransplant diabetes in patients treated with Ta-
crolimus. Mol Genet Metab 2012;105:525-7.
48. Yang J, Hutchinson II, Shah T, Min DI. Genetic and clinical 
risk factors of new-onset diabetes after transplantation in His-
panic kidney transplant recipients. Transplantation 2011;91: 
1114-9.
49. Chen Y, Sampaio MS, Yang JW, Min D, Hutchinson IV. Genet-
ic polymorphisms of the transcription factor NFATc4 and de-
velopment of new-onset diabetes after transplantation in His-
panic kidney transplant recipients. Transplantation 2012;93: 
325-30.
50. Szuszkiewicz M, Bell J, Vazquez M, Adams-Huet B, Grundy 
SM, Chandalia M, Abate N. ENPP1/PC-1 K121Q and other 
predictors of posttransplant diabetes. Metab Syndr Relat Dis-
ord 2011;9:25-9.
51. Jeong KH, Moon JY, Chung JH, Kim YH, Lee TW. Significant 
206
Lee HC
Diabetes Metab J 2012;36:199-206 http://e-dmj.org
associations between CCL5 gene polymorphisms and post-
transplantational diabetes mellitus in Korean renal allograft 
recipients. Am J Nephrol 2010;32:356-61.
52. Numakura K, Satoh S, Tsuchiya N, Horikawa Y, Inoue T, Kak-
inuma H, Matsuura S, Saito M, Tada H, Suzuki T, Habuchi T. 
Clinical and genetic risk factors for posttransplant diabetes 
mellitus in adult renal transplant recipients treated with tacro-
limus. Transplantation 2005;80:1419-24.
53. Kang ES, Magkos F, Kim BS, Zhai R, Su L, Kim YS, Christiani 
DC, Lee HC, Mantzoros CS. Variants of the adiponectin and 
adiponectin receptor-1 genes and posttransplantation diabetes 
mellitus in renal allograft recipients. J Clin Endocrinol Metab 
2012;97:E129-35.
54. Yu SJ, Peng L, Xie XB, Peng FH, Fang CH, Wang Y, Lan GB. 
Correlation between HLA and posttransplantation diabetes 
mellitus in the Han population in South China. Transplant 
Proc 2010;42:2509-12.
55. Chang HR, Yang SF, Tsai JP, Hsieh MC, Wu SW, Tsai HC, Hung 
TW, Huang JH, Lian JD. Plasminogen activator inhibitor-1 
5G/5G genotype is a protecting factor preventing posttrans-
plant diabetes mellitus. Clin Chim Acta 2011;412:322-6.
56. Tsai JP, Yang SF, Wu SW, Hung TW, Tsai HC, Lian JD, Chang 
HR. Glutathione S-transferase gene polymorphisms are not 
major risks for susceptibility to posttransplantation diabetes 
mellitus in Taiwan renal transplant recipients. J Clin Lab Anal 
2011;25:432-5.
57. Dutkiewicz G, Domanski L, Pawlik A, Binczak-Kuleta A, Saf-
ranow K, Ciechanowicz A, Dziedziejko V, Pietrzak-Nowacka 
M, Ciechanowski K. Polymorphisms of superoxide dismutase, 
glutathione peroxidase and catalase genes in patients with post-
transplant diabetes mellitus. Arch Med Res 2010;41:350-5.
58. Kang ES, Kim MS, Kim YS, Hur KY, Han SJ, Nam CM, Ahn 
CW, Cha BS, Kim SI, Lee HC. A variant of the transcription 
factor 7-like 2 (TCF7L2) gene and the risk of posttransplanta-
tion diabetes mellitus in renal allograft recipients. Diabetes Care 
2008;31:63-8.
59. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, Hur 
KY, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC. A polymor-
phism in the zinc transporter gene SLC30A8 confers resistance 
against posttransplantation diabetes mellitus in renal allograft 
recipients. Diabetes 2008;57:1043-7.
60. Kang ES, Kim MS, Kim CH, Nam CM, Han SJ, Hur KY, Ahn 
CW, Cha BS, Kim SI, Lee HC, Kim YS. Association of common 
type 2 diabetes risk gene variants and posttransplantation dia-
betes mellitus in renal allograft recipients in Korea. Transplan-
tation 2009;88:693-8.
